Table 1.

Patient Demographic and Descriptive Characteristics for the Oral Dronabinol Sample (N = 30)

Variable
Age (median)	43.5 (± 11.8; range, 21–67)
Gender (% female)	53.3
Race (% Caucasian)	96.7
Pain Site (% low back)	66.7
Pain duration (% > 5 y)	66.7
Opioid duration (% > 2 y)	70
Morphine equivalent (oral mg/d)	68.1 (SD=57.2; range, 7.5–228)
Current Opioid medication (% of subjects)
RTC
Methadone	30
Morphine - long-acting	30
Oxycodone - long-acting	16.7
PRN
Oxycodone - short acting	36.7
Morphine - short acting	16.7
Hydrocodone	6.7
Hydromorphone	6.7
Baseline levels:
Prestudy Diary (0–10)
Pain Intensity	6.9 (± 1.3)
Pain Relief	3.9 (± 1.7)
Pain Bothersomeness (0–4)	2.7 (± 0.6)
Satisfaction Baseline (0–10)	3.7 (± 2.0)
Brief Pain Inventory (0-0)
Interference with sleep	6.7 (± 3.2)
RAND-36 (0–100)
Energy/Fatigue	37.1 (± 20.8)
Pain	26.6 (± 15.2)
Social Functioning	47.8 (± 24.6)
HADS
Anxiety	6.7 (± 2.9)
Depression	6 (± 3.3)

Abbreviations: RTC, return to clinic; PRN, as needed; RAND-36, RAND 36-Health Survey; HADS, Hospital Anxiety and Depression Scale